bioRxiv · 10.1101/2021.03.27.437308
Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by Supervised Molecular Dynamics simulation
Abstract
Determining the unbinding pathways of potential small molecule compounds from their target proteins is of great significance for designing efficacious treatment solutions. One of these potential compounds is the approved HIV-1 protease inhibitor, Indinavir, which has a weak effect on the HTLV-1 protease. In this work, by employing the SuMD method, we reconstructed the unbinding pathways of Indinavir from HIV and HTLV-1 proteases to compare and understand the mechanism of the unbinding and discover the reasons for the lack of inhibitory activity against the HTLV-1 protease. We achieved multiple unbinding events from both HIV and HTLV-1 proteases. Also, we found that the mobility and fluctuations of the flap region are higher in the HTLV-1 protease, making the drug less stable. We realized that critically positioned aromatic residues such as Trp98/Trp98' and Phe67/Phe67' in the HTLV-1 protease could make strong {pi}-Stacking interactions with Indinavir, which are unfavorable for the stability of Indinavir in the active site. The details found in this study can make a reasonable explanation for the lack of inhibitory activity of this drug against HTLV-1 protease. We believe the details discovered in this work can help design more effective and more selective inhibitors for the HTLV-1 protease.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Sohraby, F., Aryapour, H.. 2021-03-28. Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by Supervised Molecular Dynamics simulation. https://doi.org/10.1101/2021.03.27.437308
Cite the original work for its findings. Save a collection to share your selection of sources.